Efficacy of Avapritinib in the PDGFRA D842V Population in Cohort 1
72%–98
GIST
The efficacy population included patients who received a starting dose of 300 mg, including 28 patients in the PDGFRA D842V population (3 in phase I and 25 in phase II). At the data cutoff date, the median follow-up was 8.6 months in the PDGFRA D842V population.Among 28 patients with PDGFRA D842V-mutant GIST receiving a starting dose of 300 mg, partial response (PR) was achieved in 21 patients as measured by IRRC assessment, resulting in an ORR of 75% (95% CI: 55%–89%) (Independent Radiology Review Committee-assessed anti-tumor efficacy

Abbreviations: 4L+, patients who received avapritinib as fourth- or later-line therapy; CI, confidence interval; Investigator-assessed anti-tumor efficacy (patients with 

Abbreviations: 4L+, patients who received avapritinib as fourth- or later-line therapy; CI, confidence interval; IRRC-assessed clinical outcomes. (Investigator-assessed clinical outcomes. (As assessed by the IRRC, Kaplan-Meier plots of the DOR and PFS indicated that the mean DOR and median PFS were not reached in the PDGFRA D842V population receiving the 300-mg dose (Kaplan-Meier plot of IRRC-assessments. (Kaplan-Meier plots of investigator assessments. (Anti-tumor efficacy assessed by Choi criteria in the PDGFRA D842V population showed that 25/28 patients achieved PR and the ORR was 89% (95% CI: 72%–98%). The CBR per Choi criteria was 89% (95% CI: 72%–98%) (Choi-assessed anti-tumor efficacy (patients with 

Abbreviations: 4L+, patients who received avapritinib as fourth- or later-line therapy; CI, confidence interval; 